GlassScriptPhysician profile
Nabil S Itani
NPI 1912009168
$17,911.34
in general payments reported to CMS, 2019-2025
55 companies · $2,307 in 2025
The $2,307 reported for 2025 was more than what 94% of Internal Medicine providers received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,902 · 2020: $2,034 · 2021: $4,004 · 2022: $2,453 · 2023: $2,543 · 2024: $2,668 · 2025: $2,307.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $7,517.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $7,517.28 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $2,803.77 | 2019-2025 | |
| Novo Nordisk INC | $2,309.85 | 2019-2025 | Ozempic, Rybelsus, Wegovy |
| Janssen Pharmaceuticals, INC | $1,463.72 | 2019-2024 | Xarelto |
| Biohaven Pharmaceuticals, INC. | $1,433.38 | 2021 | |
| Lilly USA, LLC | $1,038.94 | 2019-2025 | Mounjaro, Zepbound, Jardiance |
| Astrazeneca Pharmaceuticals LP | $1,015.37 | 2019-2025 | Airsupra, Farxiga, Breztri |
| Bayer Healthcare Pharmaceuticals INC. | $941.84 | 2021-2025 | |
| Pfizer INC. | $757.77 | 2019-2025 | |
| Sanofi-Aventis U.S. LLC | $713.87 | 2019-2023 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $605.06 | 2019-2024 | Jardiance |
| Merck Sharp & Dohme LLC | $417.45 | 2019-2025 | Verquvo, Belsomra, Capvaxive |
| Abbott Laboratories | $373.24 | 2022-2025 | Freestyle Libre 3 |
| Exact Sciences Corporation | $356.42 | 2023-2025 | Cologuard Collection Kit |
| Glaxosmithkline, LLC. | $309.82 | 2019-2025 | Trelegy Ellipta, Shingrix, Arexvy |
| Idorsia Pharmaceuticals US INC | $232.17 | 2022-2024 | Quviviq |
Show all 55 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Nabil Itani listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.